Abstract
Purpose To assess the clinical activity and toxicity of a combination chemotherapy regimen of S-1 and cisplatin in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in a retrospective study. Methods A total of 49 patients were treated in an outpatient setting with S-1 80 mg/m 2 on days 1-14 and with cisplatin 70 mg/m 2 on day 1 every 3 weeks for a maximum of six cycles as a first-line palliative chemotherapy. Patients who achieved complete response (CR), partial response (PR) or stable disease (SD) after six cycles received S-1 monotherapy as a maintenance therapy. Results The median patient age was 55 years (range 33-79), 89.8 % were male, and the Eastern Cooperative Oncology Group performance status distribution was 0/1/2 (20.4 %/73.5 %/6.1 %). Of the 43 evaluable patients, 2 (4.1 %) achieved CR and 20 (40.8 %) had a PR, for an overall response rate of 44.9 %. Thirteen patients (26.6 %) had SD. The median number of chemotherapy treatments was 4 (range 1-18). Nine patients received maintenance S-1 monotherapy after six cycles of combination chemotherapy. With a mean 10.5 months (range 1.3-25.1) of follow-up, the median progression-free and overall survival were 4.5 (95 % CI, 3.7-5.3 months) and 10.8 months (95 % CI, 5.9-15.6 months), respectively. The main grade 3-4 toxicities were neutropenia (37 %), anemia (16 %) and general weakness (8 %). Other toxicities, including nausea/ vomiting, mucositis and neuropathy, were mostly grade 1-2 and easily manageable. Conclusions The combination of S-1/cisplatin therapy had a favorable efficacy with manageable toxicity as a firstline chemotherapy regimen for advanced head and neck squamous cell carcinoma patients.
| Original language | English |
|---|---|
| Pages (from-to) | 539-546 |
| Number of pages | 8 |
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 70 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2012 Oct 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Toxicology
- Pharmacology
- Cancer Research
- Pharmacology (medical)
Cite this
}
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. / Kim, Han Sang; Kim, Hye Ryun; Kim, Gun Min; Kim, Hyo Song; Koh, Yoonwoo; Kim, Se Hun; Choi, Eun Chang; Hong, Yun Kyoung; Sung, Ji Hee; Kim, Sun Mi; Kim, Joo Hang; Cho, ByoungChul.
In: Cancer Chemotherapy and Pharmacology, Vol. 70, No. 4, 01.10.2012, p. 539-546.Research output: Contribution to journal › Article
TY - JOUR
T1 - The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
AU - Kim, Han Sang
AU - Kim, Hye Ryun
AU - Kim, Gun Min
AU - Kim, Hyo Song
AU - Koh, Yoonwoo
AU - Kim, Se Hun
AU - Choi, Eun Chang
AU - Hong, Yun Kyoung
AU - Sung, Ji Hee
AU - Kim, Sun Mi
AU - Kim, Joo Hang
AU - Cho, ByoungChul
PY - 2012/10/1
Y1 - 2012/10/1
N2 - Purpose To assess the clinical activity and toxicity of a combination chemotherapy regimen of S-1 and cisplatin in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in a retrospective study. Methods A total of 49 patients were treated in an outpatient setting with S-1 80 mg/m 2 on days 1-14 and with cisplatin 70 mg/m 2 on day 1 every 3 weeks for a maximum of six cycles as a first-line palliative chemotherapy. Patients who achieved complete response (CR), partial response (PR) or stable disease (SD) after six cycles received S-1 monotherapy as a maintenance therapy. Results The median patient age was 55 years (range 33-79), 89.8 % were male, and the Eastern Cooperative Oncology Group performance status distribution was 0/1/2 (20.4 %/73.5 %/6.1 %). Of the 43 evaluable patients, 2 (4.1 %) achieved CR and 20 (40.8 %) had a PR, for an overall response rate of 44.9 %. Thirteen patients (26.6 %) had SD. The median number of chemotherapy treatments was 4 (range 1-18). Nine patients received maintenance S-1 monotherapy after six cycles of combination chemotherapy. With a mean 10.5 months (range 1.3-25.1) of follow-up, the median progression-free and overall survival were 4.5 (95 % CI, 3.7-5.3 months) and 10.8 months (95 % CI, 5.9-15.6 months), respectively. The main grade 3-4 toxicities were neutropenia (37 %), anemia (16 %) and general weakness (8 %). Other toxicities, including nausea/ vomiting, mucositis and neuropathy, were mostly grade 1-2 and easily manageable. Conclusions The combination of S-1/cisplatin therapy had a favorable efficacy with manageable toxicity as a firstline chemotherapy regimen for advanced head and neck squamous cell carcinoma patients.
AB - Purpose To assess the clinical activity and toxicity of a combination chemotherapy regimen of S-1 and cisplatin in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in a retrospective study. Methods A total of 49 patients were treated in an outpatient setting with S-1 80 mg/m 2 on days 1-14 and with cisplatin 70 mg/m 2 on day 1 every 3 weeks for a maximum of six cycles as a first-line palliative chemotherapy. Patients who achieved complete response (CR), partial response (PR) or stable disease (SD) after six cycles received S-1 monotherapy as a maintenance therapy. Results The median patient age was 55 years (range 33-79), 89.8 % were male, and the Eastern Cooperative Oncology Group performance status distribution was 0/1/2 (20.4 %/73.5 %/6.1 %). Of the 43 evaluable patients, 2 (4.1 %) achieved CR and 20 (40.8 %) had a PR, for an overall response rate of 44.9 %. Thirteen patients (26.6 %) had SD. The median number of chemotherapy treatments was 4 (range 1-18). Nine patients received maintenance S-1 monotherapy after six cycles of combination chemotherapy. With a mean 10.5 months (range 1.3-25.1) of follow-up, the median progression-free and overall survival were 4.5 (95 % CI, 3.7-5.3 months) and 10.8 months (95 % CI, 5.9-15.6 months), respectively. The main grade 3-4 toxicities were neutropenia (37 %), anemia (16 %) and general weakness (8 %). Other toxicities, including nausea/ vomiting, mucositis and neuropathy, were mostly grade 1-2 and easily manageable. Conclusions The combination of S-1/cisplatin therapy had a favorable efficacy with manageable toxicity as a firstline chemotherapy regimen for advanced head and neck squamous cell carcinoma patients.
UR - http://www.scopus.com/inward/record.url?scp=84867582501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867582501&partnerID=8YFLogxK
U2 - 10.1007/s00280-012-1933-8
DO - 10.1007/s00280-012-1933-8
M3 - Article
C2 - 22868340
AN - SCOPUS:84867582501
VL - 70
SP - 539
EP - 546
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 4
ER -